Gables Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-419,181
| Closed | -$13.2M | – | 503 |
|
|
2026
Q2 | $13.2M | Sell |
419,181
-5,400
| -1% | -$159K | 4.76% | 3 |
|
|
2026
Q1 | $10.5M | Sell |
424,581
-40
| -0% | -$953 | 4.44% | 3 |
|
|
2025
Q4 | $9.9M | Sell |
424,621
-10,800
| -2% | -$241K | 4.19% | 4 |
|
|
2025
Q3 | $8.58M | Buy |
435,421
+26,400
| +6% | +$543K | 3.68% | 4 |
|
|
2025
Q2 | $8.88M | Sell |
409,021
-7,350
| -2% | -$174K | 4.2% | 4 |
|
|
2025
Q1 | $10.1M | Sell |
416,371
-1,180
| -0.3% | -$26.6K | 4.99% | 3 |
|
|
2024
Q4 | $8.71M | Sell |
417,551
-9,700
| -2% | -$208K | 4.2% | 3 |
|
|
2024
Q3 | $8.49M | Sell |
427,251
-4,959
| -1% | -$91.9K | 4.28% | 3 |
|
|
2024
Q2 | $6.69M | Sell |
432,210
-4,450
| -1% | -$69.3K | 3.5% | 3 |
|
|
2024
Q1 | $6.96M | Buy |
436,660
+2,400
| +0.6% | +$36.2K | 3.83% | 3 |
|
|
2023
Q4 | $7.3M | Buy |
434,260
+2,305
| +0.5% | +$31.5K | 4.54% | 3 |
|
|
2023
Q3 | $5.05M | Sell |
431,955
-2,975
| -0.7% | -$39.8K | 3.51% | 3 |
|
|
2023
Q2 | $5.85M | Buy |
434,930
+25,850
| +6% | +$372K | 3.83% | 3 |
|
|
2023
Q1 | $6.78M | Sell |
409,080
-13,525
| -3% | -$223K | 4.74% | 2 |
|
|
2022
Q4 | $7.86M | Sell |
422,605
-11,209
| -3% | -$173K | 5.72% | 2 |
|
|
2022
Q3 | $5.57M | Sell |
433,814
-1,950
| -0.4% | -$23.1K | 4.46% | 2 |
|
|
2022
Q2 | $3.06M | Sell |
435,764
-3,000
| -0.7% | -$22K | 2.31% | 8 |
|
|
2022
Q1 | $3.64M | Sell |
438,764
-10,400
| -2% | -$73.5K | 2.28% | 9 |
|
|
2021
Q4 | $3.04M | Buy |
449,164
+57,600
| +15% | +$379K | 1.81% | 13 |
|
|
2021
Q3 | $2.08M | Buy |
391,564
+49,600
| +15% | +$271K | 1.35% | 21 |
|
|
2021
Q2 | $1.97M | Sell |
341,964
-65,100
| -16% | -$336K | 1.31% | 23 |
|
|
2021
Q1 | $1.88M | Sell |
407,064
-6,300
| -2% | -$25K | 1.04% | 31 |
|
|
2020
Q4 | $1.38M | Sell |
413,364
-19,500
| -5% | -$65.5K | 0.81% | 37 |
|
|
2020
Q3 | $1.29M | Sell |
432,864
-74,000
| -15% | -$289K | 0.82% | 34 |
|
|
2020
Q2 | $2.34M | Sell |
506,864
-6,000
| -1% | -$27K | 1.62% | 18 |
|
|
2020
Q1 | $1.98M | Sell |
512,864
-5,000
| -1% | -$20.5K | 1.63% | 19 |
|
|
2019
Q4 | $1.94M | Buy |
517,864
+27,300
| +6% | +$128K | 1.3% | 25 |
|
|
2019
Q3 | $2.61M | Buy |
490,564
+4,500
| +0.9% | +$24K | 1.84% | 13 |
|
|
2019
Q2 | $1.87M | Buy |
486,064
+6,300
| +1% | +$27.2K | 1.52% | 20 |
|
|
2019
Q1 | $2.45M | Sell |
479,764
-1,000
| -0.2% | -$2.94K | 1.97% | 15 |
|
|
2018
Q4 | $923K | Buy |
480,764
+32,500
| +7% | +$93K | 0.8% | 37 |
|
|
2018
Q3 | $1.69M | Buy |
448,264
+3,000
| +0.7% | +$9.4K | 1.29% | 25 |
|
|
2018
Q2 | $1.51M | Sell |
445,264
-13,600
| -3% | -$41.3K | 1.23% | 25 |
|
|
2018
Q1 | $1.1M | Buy |
+458,864
| New | +$1.52M | 0.97% | 33 |
|
Other funds holding CPRX
Gables Capital Management's CPRX Position: Q3 2026 in Review
Gables Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 419,181 shares — an estimated $13.2M sold.
Gables Capital Management first reported a position in CPRX in Q1 2018 and held it in 34 quarters. The position peaked at $13.2M in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.
- Gables Capital Management reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- Gables Capital Management sold 419,181 Catalyst Pharmaceutical shares in Q3 2026, an estimated $13.2M.
- Gables Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2018 and held it in 34 quarters.
- Gables Capital Management's Catalyst Pharmaceutical position peaked at $13.2M in Q2 2026.
- 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on Gables Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.